A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
The standard treatment for locally advanced rectal cancer involves chemotherapy and
radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and
radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a
standard and important part of treatment for rectal cancer and has been shown to decrease
the risk of the cancer coming back in the same area in the pelvis, some patients experience
undesirable side effects from the radiation and there have been important advances in
chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is
to compare the effects, both good and bad, of the standard treatment of chemotherapy and
radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs
5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard
treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA
(Food and Drug Administration) approved and have been used routinely to treat patients with
advanced colorectal cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.